29.09
price down icon0.82%   -0.24
pre-market  Pre-mercato:  29.06   -0.03   -0.10%
loading
Precedente Chiudi:
$29.33
Aprire:
$29.33
Volume 24 ore:
3.63M
Relative Volume:
2.18
Capitalizzazione di mercato:
$5.14B
Reddito:
$1.51B
Utile/perdita netta:
$333.35M
Rapporto P/E:
14.92
EPS:
1.95
Flusso di cassa netto:
$315.22M
1 W Prestazione:
-2.48%
1M Prestazione:
-8.15%
6M Prestazione:
-2.09%
1 anno Prestazione:
+16.13%
Intervallo 1D:
Value
$28.92
$29.68
Intervallo di 1 settimana:
Value
$28.92
$30.52
Portata 52W:
Value
$22.90
$36.45

Alkermes Plc Stock (ALKS) Company Profile

Name
Nome
Alkermes Plc
Name
Telefono
00-353-1-772-8000
Name
Indirizzo
CONNAUGHT HOUSE, DUBLIN 4
Name
Dipendente
1,800
Name
Cinguettio
@alkermes
Name
Prossima data di guadagno
2024-10-24
Name
Ultimi documenti SEC
Name
ALKS's Discussions on Twitter

Confronta ALKS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
ALKS
Alkermes Plc
29.09 5.14B 1.51B 333.35M 315.22M 1.95
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
38.01 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
157.17 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.41 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.77 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.95 20.17B 16.54B -1.64B 749.00M -1.45

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-28 Iniziato Needham Buy
2025-03-13 Iniziato RBC Capital Mkts Sector Perform
2025-03-04 Aggiornamento UBS Sell → Neutral
2025-02-11 Iniziato Deutsche Bank Buy
2024-11-05 Aggiornamento Stifel Hold → Buy
2024-06-17 Iniziato TD Cowen Buy
2024-03-19 Iniziato Robert W. Baird Outperform
2024-02-20 Downgrade UBS Neutral → Sell
2023-11-20 Ripresa JP Morgan Neutral
2023-10-24 Aggiornamento Evercore ISI In-line → Outperform
2023-10-17 Iniziato UBS Neutral
2022-11-03 Aggiornamento Piper Sandler Neutral → Overweight
2022-10-14 Aggiornamento BofA Securities Underperform → Neutral
2022-08-16 Iniziato Piper Sandler Neutral
2022-04-22 Ripresa Goldman Buy
2022-04-20 Iniziato Goldman Buy
2022-01-27 Aggiornamento Cantor Fitzgerald Hold → Overweight
2021-12-01 Iniziato Citigroup Neutral
2021-10-07 Aggiornamento Jefferies Hold → Buy
2021-09-02 Downgrade BofA Securities Neutral → Underperform
2020-10-15 Aggiornamento Mizuho Neutral → Buy
2020-07-30 Downgrade Goldman Neutral → Sell
2020-02-14 Downgrade BofA/Merrill Buy → Neutral
2020-02-14 Reiterato H.C. Wainwright Neutral
2020-02-14 Downgrade JP Morgan Overweight → Neutral
2020-02-06 Iniziato Mizuho Neutral
2020-01-31 Aggiornamento Wolfe Research Underperform → Peer Perform
2019-09-05 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2019-07-15 Aggiornamento Goldman Sell → Neutral
2019-05-31 Iniziato H.C. Wainwright Neutral
2019-05-01 Downgrade Citigroup Buy → Neutral
2018-12-19 Downgrade Goldman Neutral → Sell
2018-12-14 Iniziato Wolfe Research Underperform
2018-12-13 Downgrade Credit Suisse Outperform → Underperform
2018-11-05 Iniziato Piper Jaffray Neutral
2018-08-07 Iniziato Stifel Hold
2018-06-21 Downgrade Morgan Stanley Equal-Weight → Underweight
2018-06-06 Iniziato B. Riley FBR, Inc. Buy
2018-05-16 Aggiornamento Citigroup Neutral → Buy
2018-05-11 Iniziato BofA/Merrill Buy
Mostra tutto

Alkermes Plc Borsa (ALKS) Ultime notizie

pulisher
Jun 18, 2025

Alkermes (ALKS) Upgraded by UBS with Positive Development Prospe - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Alkermes stock upgraded at UBS on sleep disorder drug (ALKS) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes Gains Momentum With Promising Narcolepsy Drug - Finimize

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes' ALKS-2680 Seen as Potential Breakthrough for Narcolepsy, Hypersomnia, BofA Says - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes (ALKS) Gains Upgrade from UBS with Positive Outlook | A - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes (ALKS) Gains Upgrade from UBS with Positive Outlook | ALKS Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes (ALKS) Receives Buy Rating Upgrade from UBS | ALKS Stoc - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

This Cooper Companies Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes (ALKS) Receives Buy Rating Upgrade from UBS | ALKS Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

UBS Upgrades Alkermes Public to Buy From Neutral, Adjusts Price Target to $42 From $33 - marketscreener.com

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes (ALKS) Receives Upgrade as Prospects Brighten for Narco - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes (ALKS) Receives Upgrade as Prospects Brighten for Narcolepsy Treatment | ALKS Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 12, 2025

When (ALKS) Moves Investors should Listen - news.stocktradersdaily.com

Jun 12, 2025
pulisher
Jun 12, 2025

Substance Abuse Treatment Market Size, Trends & Growth - openPR.com

Jun 12, 2025
pulisher
Jun 10, 2025

Insider Sell: Christian Nichols Sells Shares of Alkermes PLC - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

RBC Capital maintains Alkermes stock rating amid safety concerns By Investing.com - Investing.com Nigeria

Jun 10, 2025
pulisher
Jun 10, 2025

GAMMA Investing LLC Grows Position in Alkermes plc (NASDAQ:ALKS) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Transcript : Alkermes plc Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Alkermes at Goldman Sachs Healthcare: Strategic Moves in Sleep Disorders By Investing.com - Investing.com Nigeria

Jun 09, 2025
pulisher
Jun 09, 2025

Alkermes at Goldman Sachs Healthcare: Strategic Moves in Sleep Disorders - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

Alkermes To Present At Goldman Sachs Global Conference; Webcast At 10:00 AM ET - Nasdaq

Jun 09, 2025
pulisher
Jun 06, 2025

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire

Jun 06, 2025
pulisher
Jun 06, 2025

Fed. Circ. Weighs Purview Over Acorda's $17M Arbitral Award - Law360

Jun 06, 2025
pulisher
Jun 05, 2025

Substance Abuse Treatment Market Set to Witness Digital and Personalized Care Expansion | Indivior, Alkermes - openPR.com

Jun 05, 2025
pulisher
Jun 05, 2025

Controlled Release Drug Delivery Market Is Booming So Rapidly - openPR.com

Jun 05, 2025
pulisher
Jun 05, 2025

Nanotechnology Drug Delivery Market Set to Witness Significant - openPR.com

Jun 05, 2025
pulisher
Jun 04, 2025

Alkermes plc (NASDAQ:ALKS) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences - The Malaysian Reserve

Jun 03, 2025
pulisher
Jun 02, 2025

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - StreetInsider

Jun 02, 2025
pulisher
Jun 02, 2025

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference | ALKS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Opioid Use Disorder Market Projected to Witness Massive GrowthIndivior PLC, Alkermes plc - openPR.com

Jun 02, 2025
pulisher
May 31, 2025

Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 48% Undervaluation? - simplywall.st

May 31, 2025
pulisher
May 31, 2025

Where are the Opportunities in (ALKS) - news.stocktradersdaily.com

May 31, 2025
pulisher
May 31, 2025

Cetera Investment Advisers Increases Stock Position in Alkermes plc (NASDAQ:ALKS) - Defense World

May 31, 2025
pulisher
May 29, 2025

Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 20 - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 2025 | ALKS Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 - goSkagit

May 29, 2025
pulisher
May 29, 2025

Global Healthcare & Medical Tourism News - Medical Tourism Magazine

May 29, 2025
pulisher
May 28, 2025

This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

May 28, 2025
pulisher
May 28, 2025

Needham's Positive Outlook on Alkermes (ALKS) with Promising Sal - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Needham Initiates Alkermes Public at Buy With $45 Price Target - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Needham Initiates Coverage on Alkermes (ALKS) with Buy Rating | ALKS Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Needham's Positive Outlook on Alkermes (ALKS) with Promising Sales Projections | ALKS Stock News - GuruFocus

May 28, 2025
pulisher
May 27, 2025

Quantinno Capital Management LP Acquires New Position in Alkermes plc (NASDAQ:ALKS) - Defense World

May 27, 2025
pulisher
May 23, 2025

Controlled Release Drug Delivery Market Generated - openPR.com

May 23, 2025
pulisher
May 23, 2025

Bank of America Corp DE Trims Stake in Alkermes plc (NASDAQ:ALKS) - Defense World

May 23, 2025
pulisher
May 21, 2025

Alkermes Shareholders Approve Amendments at Annual Meeting - TipRanks

May 21, 2025
pulisher
May 20, 2025

(ALKS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 20, 2025
pulisher
May 20, 2025

Alkermes price target raised to $35 from $34 at BofA - MSN

May 20, 2025

Alkermes Plc Azioni (ALKS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Alkermes Plc Azioni (ALKS) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Nichols Christian Todd
SVP, Chief Commercial Officer
Jun 10 '25
Sale
31.09
3,334
103,654
86,208
$13.46
price up icon 0.98%
$8.87
price up icon 1.14%
$126.55
price down icon 0.60%
$290.75
price down icon 0.33%
drug_manufacturers_specialty_generic RDY
$15.23
price up icon 0.26%
$16.95
price down icon 0.64%
Capitalizzazione:     |  Volume (24 ore):